| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 606.62 KB | Adobe PDF |
Advisor(s)
Abstract(s)
This systematic review aimed to evaluate the potential anti-inflammatory effect of Rosmarinus officinalis in preclinical in vivo models of inflammation. A search was conducted in the databases PubMed, Scopus, and Web of Science, with related keywords. The inclusion criteria were inflammation, plant, and studies on rats or mice; while, the exclusion criteria were reviews, studies with in vitro models, and associated plants. The predominant animal models were paw edema, acute liver injury, and asthma. Rosemary was more commonly used in its entirety than in compounds, and the prevalent methods of extraction were maceration and hydrodistillation. The most common routes of administration reported were gavage, intraperitoneal, and oral, on a route-dependent dosage. The treatment took place daily, or was single-dose, on average for 21 days, and it more often started before the induction. The most evaluated biomarkers were tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-10, myeloperoxidase (MPO), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx), malondialdehyde (MDA), and superoxide dismutase (SOD). The best results emerged at a dose of 60 mg/kg, via IP of carnosic acid, a dose of 400 mg/kg via gavage of Rosmarinus officinalis, and a dose of 10 mg/kg via IP of rosmarinic acid. Rosmarinus officinalis L. showed anti-inflammatory activity before and after induction of treatments.
Description
FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.
Keywords
Inflammation Rosmarinus officinalis L Rosmarinus Rosmarinic acid Carnosic acid Carnosol Rats Mice Mouse FCT_UIDB/05608/2020 FCT_UIDP/05608/2020
Citation
Gonçalves C, Fernandes D, Silva IJ, Mateus V. Potential anti-inflammatory effect of Rosmarinus officinalis in preclinical in vivo models of inflammation. Molecules. 2022;27(3):609.
Publisher
MDPI